LLY Quote, Financials, Valuation and Earnings

Biogen has a net margin of 21.68% compared to Eli Lilly and's net margin of 9.89%. Eli Lilly and's return on equity of 78.25% beat Biogen's return on equity of 9.11%.

Eli Lilly and has a consensus price target of $981.63, signalling upside risk potential of 19.18%. On the other hand Biogen has an analysts' consensus of $175.82 which suggests that it could grow by 42.33%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Biogen quarterly revenues of $2.4B. Eli Lilly and's net income of $2.8B is higher than Biogen's net income of $240.5M. Notably, Eli Lilly and's price-to-earnings ratio is 67.02x while Biogen's PE ratio is 12.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 15.18x versus 1.84x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.68% compared to Eli Lilly and's net margin of -907.48%. Eli Lilly and's return on equity of 78.25% beat Moderna's return on equity of -29.23%.

Eli Lilly and has a consensus price target of $981.63, signalling upside risk potential of 19.18%. On the other hand Moderna has an analysts' consensus of $46.92 which suggests that it could grow by 69.93%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Moderna quarterly revenues of $107M. Eli Lilly and's net income of $2.8B is higher than Moderna's net income of -$971M. Notably, Eli Lilly and's price-to-earnings ratio is 67.02x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 15.18x versus 3.42x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 21.68% compared to Eli Lilly and's net margin of 26.7%. Eli Lilly and's return on equity of 78.25% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Eli Lilly and has a consensus price target of $981.63, signalling upside risk potential of 19.18%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 32.46%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Eli Lilly and's net income of $2.8B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Eli Lilly and's price-to-earnings ratio is 67.02x while Regeneron Pharmaceuticals's PE ratio is 15.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 15.18x versus 4.91x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 21.68% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 78.25% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $981.63, signalling upside risk potential of 19.18%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 207.44%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.479, which suggesting that the stock is 52.104% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Eli Lilly and has a quarterly dividend of $1.50 per share corresponding to a yield of 0.66%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 44.2% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $12.7B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $2.8B is higher than Viking Therapeutics's net income of -$45.6M. Notably, Eli Lilly and's price-to-earnings ratio is 67.02x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 15.18x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.